AR106478A1 - Combinación sinérgica farmacéutica - Google Patents
Combinación sinérgica farmacéuticaInfo
- Publication number
- AR106478A1 AR106478A1 ARP160103264A ARP160103264A AR106478A1 AR 106478 A1 AR106478 A1 AR 106478A1 AR P160103264 A ARP160103264 A AR P160103264A AR P160103264 A ARP160103264 A AR P160103264A AR 106478 A1 AR106478 A1 AR 106478A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically effective
- fimasartan
- effective salts
- nep
- inhibitor
- Prior art date
Links
- 230000002195 synergetic effect Effects 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 5
- 239000003112 inhibitor Substances 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 239000005475 Fimasartan Substances 0.000 abstract 3
- AMEROGPZOLAFBN-UHFFFAOYSA-N fimasartan Chemical compound CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 AMEROGPZOLAFBN-UHFFFAOYSA-N 0.000 abstract 3
- 229960003489 fimasartan Drugs 0.000 abstract 3
- -1 4-phenylphenyl Chemical group 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composición sinérgica conformada por Fimasartán o sus sales farmacéuticamente efectivas, y un inhibidor de NEP o sus sales farmacéuticamente efectivas, para el tratamiento de enfermedades cardiovasculares y enfermedades relacionadas. Combinación sinérgica que comprende combinaciones de Fimasartán o sus sales farmacéuticamente efectivas adecuadas, y un inhibidor de NEP o sus sales farmacéuticamente efectivas, en una composición farmacéutica en una sola unidad. Combinar las composiciones farmacéuticas separadas de Fimasartán y un inhibidor de NEP en forma de kit. Métodos para preparar dichas composiciones farmacéuticas por separado en forma de kit que contiene ambos agentes activos, y con métodos para tratar un sujeto con las mismas. Reivindicación 2: La composición farmacéutica de acuerdo con la reivindicación 1, caracterizada porque el inhibidor de NEP es ácido (4-[[(2S,4R)-5-etoxi-4-metil-5-oxo-1-(4-fenilfenil)pentan-2-il]amino]-4-oxobutanoico o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4103MU2015 | 2015-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106478A1 true AR106478A1 (es) | 2018-01-17 |
Family
ID=57345990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103264A AR106478A1 (es) | 2015-10-29 | 2016-10-26 | Combinación sinérgica farmacéutica |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20180311241A1 (es) |
| AR (1) | AR106478A1 (es) |
| TW (1) | TW201729801A (es) |
| WO (1) | WO2017072636A1 (es) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4610816A (en) | 1980-12-18 | 1986-09-09 | Schering Corporation | Substituted dipeptides as inhibitors of enkephalinases |
| ZA84670B (en) | 1983-01-31 | 1985-09-25 | Merck & Co Inc | Thiorphan analogs as enkephalinase and angiotensin converting enzyme inhibitors |
| US4722810A (en) | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
| US4929641B1 (en) | 1988-05-11 | 1994-08-30 | Schering Corp | Mercapto-acylamino acid antihypertensives |
| GB8811873D0 (en) | 1988-05-19 | 1988-06-22 | Pfizer Ltd | Therapeutic agents |
| GB8812597D0 (en) | 1988-05-27 | 1988-06-29 | Pfizer Ltd | Therapeutic agents |
| GB2218983A (en) | 1988-05-27 | 1989-11-29 | Pfizer Ltd | Spiro-substituted glutaramides as diuretics |
| EP0361365A1 (en) | 1988-09-30 | 1990-04-04 | E.R. SQUIBB & SONS, INC. | Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use |
| GB8903740D0 (en) | 1989-02-18 | 1989-04-05 | Pfizer Ltd | Therapeutic agents |
| US5223516A (en) | 1990-03-22 | 1993-06-29 | E. R. Squibb & Sons, Inc. | 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same |
| GB9103454D0 (en) | 1991-02-19 | 1991-04-03 | Pfizer Ltd | Therapeutic agents |
| US5294632A (en) | 1991-05-01 | 1994-03-15 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipetide derivatives |
| US5250522A (en) | 1992-10-09 | 1993-10-05 | Ciba-Geigy Corporation | Phosphono/biaryl substituted amino acid derivatives |
| US5273990A (en) | 1992-09-03 | 1993-12-28 | Ciba-Geigy Corporation | Phosphono substituted tetrazole derivatives |
| GB9123353D0 (en) | 1991-11-04 | 1991-12-18 | Fujisawa Pharmaceutical Co | New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
| WO1993010773A1 (en) | 1991-12-06 | 1993-06-10 | Schering-Plough S.P.A. | Use of neutral endopeptidase inhibitors in the treatment of left ventricular hypertrophy |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| DE4233296C1 (de) | 1992-10-02 | 1994-03-31 | Heitland Und Petre Int Gmbh | Behälter für Kosmetikprodukte |
| WO1994015908A1 (fr) | 1993-01-14 | 1994-07-21 | Yoshitomi Pharmaceutical Industries, Ltd. | Derive de propionamide et son utilisation medicinale |
| JPH06234754A (ja) | 1993-02-10 | 1994-08-23 | Dai Ichi Seiyaku Co Ltd | 複素環式カルボン酸誘導体 |
| IT1266571B1 (it) | 1993-07-30 | 1997-01-09 | Zambon Spa | Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari |
| JP3576193B2 (ja) | 1993-12-03 | 2004-10-13 | 第一製薬株式会社 | ビフェニルメチル置換バレリルアミド誘導体 |
| AU2005256634B2 (en) * | 2004-06-23 | 2010-12-09 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1-receptor antagonists |
| WO2007045663A2 (en) * | 2005-10-19 | 2007-04-26 | Novartis Ag | Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure |
| CN105693543B (zh) * | 2014-12-15 | 2018-08-10 | 四川海思科制药有限公司 | 沙库比曲类衍生物、其药物组合物、制备方法及用途 |
-
2016
- 2016-10-20 US US15/771,334 patent/US20180311241A1/en not_active Abandoned
- 2016-10-20 WO PCT/IB2016/056311 patent/WO2017072636A1/en not_active Ceased
- 2016-10-26 AR ARP160103264A patent/AR106478A1/es unknown
- 2016-10-27 TW TW105134674A patent/TW201729801A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180311241A1 (en) | 2018-11-01 |
| TW201729801A (zh) | 2017-09-01 |
| WO2017072636A1 (en) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003542A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
| CO2020001743A2 (es) | Métodos de tratamiento para la fibrosis quística | |
| ECSP13012658A (es) | Composiciones y métodos para el tratamiento de la mielofibrosis | |
| MX378867B (es) | Inhibidores de la nep para el tratamiento de enfermedades caracterizadas por el ensanchamiento o remodelacion auricular. | |
| CO6650415A2 (es) | Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa | |
| MX384721B (es) | Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf. | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| MX2018008694A (es) | Metodos y composiciones para tratar la hiperhidrosis. | |
| MX2019002774A (es) | Inhibidores de la recirculacion de acidos biliares para el tratamiento de hipercolemia y enfermedad hepatica colestasica. | |
| BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| CO2019013047A2 (es) | Composiciones sólidas para administración oral | |
| AR087107A1 (es) | Compuesto inhibidor de la señalizacion de la trayectoria notch | |
| MX350666B (es) | Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia. | |
| PE20160194A1 (es) | Composiciones y metodos para tratar anemia | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| CO2020010193A2 (es) | Una composición farmacéutica para la anemia | |
| BR112017010439A2 (pt) | composto, composição farmacêutica, combinação farmacêutica, kit, métodos para controle de uma doença fúngica em uma planta e para prevenção ou tratamento de doença fúngica em um indivíduo, e, uso de um composto | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| MX390332B (es) | Una composición farmacéutica que comprende febuxostat e inosina para usarse en el tratamiento de enfermedades en donde existe una deficiencia de atp intracelular. | |
| AR087902A1 (es) | COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF | |
| BR112020008258B8 (pt) | Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido) | |
| CO2017008115A2 (es) | Ácido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico | |
| UA112418C2 (uk) | Терапевтичний болезаспокійливий засіб | |
| CO2017008426A2 (es) | Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |